101 related articles for article (PubMed ID: 8168997)
1. Evaluation of the secretory component as a prognostic variable in colorectal carcinoma.
Koretz K; Schlag P; Quentmeier A; Möller P
Int J Cancer; 1994 May; 57(3):365-70. PubMed ID: 8168997
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of secretory component, secretory IgA and carcinoembryonic antigen in large bowel carcinomas.
Rognum TO; Brandtzaeg P; Orjasaeter H; Elgjo K; Hognestad J
Pathol Res Pract; 1980 Dec; 170(1-3):126-45. PubMed ID: 18788158
[TBL] [Abstract][Full Text] [Related]
3. Large-bowel carcinomas with different ploidy, related to secretory component, IgA, and CEA in epithelium and plasma.
Rognum TO; Thorud E; Elgjo K; Brandtzaeg P; Orjasaeter H; Nygaard K
Br J Cancer; 1982 Jun; 45(6):921-34. PubMed ID: 7046779
[TBL] [Abstract][Full Text] [Related]
4. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas.
Koretz K; Brüderlein S; Henne C; Möller P
Br J Cancer; 1992 Nov; 66(5):810-4. PubMed ID: 1384641
[TBL] [Abstract][Full Text] [Related]
5. The value of secretory component (SC) immunoreactivity in diagnosis and prognosis of colorectal carcinomas.
Arends JW; Wiggers T; Thijs CT; Verstijnen C; Swaen GJ; Bosman FT
Am J Clin Pathol; 1984 Sep; 82(3):267-74. PubMed ID: 6465093
[TBL] [Abstract][Full Text] [Related]
6. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium.
Möller P; Koretz K; Leithäuser F; Brüderlein S; Henne C; Quentmeier A; Krammer PH
Int J Cancer; 1994 May; 57(3):371-7. PubMed ID: 8168998
[TBL] [Abstract][Full Text] [Related]
7. Secretory component mRNA and protein expression in colorectal adenomas and carcinomas.
Krajci P; Meling GI; Andersen SN; Hofstad B; Vatn MH; Rognum TO; Brandtzaeg P
Br J Cancer; 1996 Jun; 73(12):1503-10. PubMed ID: 8664120
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of secretory component by colonic neoplasms.
Poger ME; Hirsch BR; Lamm ME
Am J Pathol; 1976 Feb; 82(2):327-38. PubMed ID: 175662
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium.
Koretz K; Brüderlein S; Henne C; Möller P
Br J Cancer; 1993 Nov; 68(5):926-31. PubMed ID: 7692919
[TBL] [Abstract][Full Text] [Related]
10. Immunoperoxidase study of the secretory immunoglobulin system in colonic neoplasia.
Isaacson P
J Clin Pathol; 1982 Jan; 35(1):14-25. PubMed ID: 6801094
[TBL] [Abstract][Full Text] [Related]
11. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of alpha-1-antitrypsin in early stage of colorectal carcinomas.
Karashima S; Kataoka H; Itoh H; Maruyama R; Koono M
Int J Cancer; 1990 Feb; 45(2):244-50. PubMed ID: 2303291
[TBL] [Abstract][Full Text] [Related]
13. Sporadic loss of leucocyte-function-associated antigen-3 (LFA-3) in colorectal carcinomas.
Koretz K; Schlag P; Möller P
Virchows Arch A Pathol Anat Histopathol; 1991; 419(5):389-94. PubMed ID: 1721470
[TBL] [Abstract][Full Text] [Related]
14. Cell lineage markers in premalignant and malignant colonic mucosa.
Ho SB; Itzkowitz SH; Friera AM; Jiang SH; Kim YS
Gastroenterology; 1989 Aug; 97(2):392-404. PubMed ID: 2663612
[TBL] [Abstract][Full Text] [Related]
15. Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors.
Saeki T; Stromberg K; Qi CF; Gullick WJ; Tahara E; Normanno N; Ciardiello F; Kenney N; Johnson GR; Salomon DS
Cancer Res; 1992 Jun; 52(12):3467-73. PubMed ID: 1596904
[TBL] [Abstract][Full Text] [Related]
16. Tenascin-C tissue concentration in inflammatory and neoplastic diseases of the colon mucosa.
Riedl S; Kadmon M; Tandara A; Hinz U; Möller P; Faissner A
Anticancer Res; 1997; 17(4B):3165-6. PubMed ID: 9329627
[TBL] [Abstract][Full Text] [Related]
17. Distribution of immunoglobulin-containing cells and localization of secretory component in gastric mucosa bearing carcinoma.
Togo S; Hirayama R; Hirokawa K
Bull Tokyo Med Dent Univ; 1981 Jun; 28(2):61-75. PubMed ID: 7018724
[TBL] [Abstract][Full Text] [Related]
18. For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.
Caplin S; Cerottini JP; Bosman FT; Constanda MT; Givel JC
Cancer; 1998 Aug; 83(4):666-72. PubMed ID: 9708929
[TBL] [Abstract][Full Text] [Related]
19. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
Br J Cancer; 1997; 75(12):1793-801. PubMed ID: 9192984
[TBL] [Abstract][Full Text] [Related]
20. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis.
Haber RS; Rathan A; Weiser KR; Pritsker A; Itzkowitz SH; Bodian C; Slater G; Weiss A; Burstein DE
Cancer; 1998 Jul; 83(1):34-40. PubMed ID: 9655290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
